Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV

NCT00363545 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00363545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00363545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2006
Completion date
April 12, 2007
Enrollment
1,274 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus